{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T07:15:26Z","timestamp":1775373326390,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002745","name":"Bayerische Forschungsstiftung","doi-asserted-by":"publisher","award":["AZ-872-09\/4SC\/MM"],"award-info":[{"award-number":["AZ-872-09\/4SC\/MM"]}],"id":[{"id":"10.13039\/501100002745","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["2011.085.1\u20132"],"award-info":[{"award-number":["2011.085.1\u20132"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["MA1289\/7-3"],"award-info":[{"award-number":["MA1289\/7-3"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australian National Health and Medical Research Council","award":["APP1127717"],"award-info":[{"award-number":["APP1127717"]}]},{"name":"Australia-Germany Joint Research Cooperation Scheme","award":["RG162050\/54390135"],"award-info":[{"award-number":["RG162050\/54390135"]}]},{"name":"Proteomics French Infrastructure","award":["ANR-10-INBS-08-01"],"award-info":[{"award-number":["ANR-10-INBS-08-01"]}]},{"name":"Labex GRAL","award":["ANR-10-LABX-49-01"],"award-info":[{"award-number":["ANR-10-LABX-49-01"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.antiviral.2018.09.012","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T17:42:50Z","timestamp":1538070170000},"page":"84-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activity"],"prefix":"10.1016","volume":"159","author":[{"given":"Friedrich","family":"Hahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corina","family":"Hutterer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart T.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanife","family":"Strojan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Kraut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Kohrt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Wangen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Pfizer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3896-6196","authenticated-orcid":false,"given":"Yohann","family":"Cout\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Rawlinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Strobl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Marschall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.09.012_bib1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jviromet.2011.03.005","article-title":"A reporter system for Epstein-Barr virus (EBV) lytic replication: anti-EBV activity of the broad anti-herpesviral drug artesunate","volume":"173","author":"Auerochs","year":"2011","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.antiviral.2018.09.012_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/13543784.2017.1274733","article-title":"Letermovir for the management of cytomegalovirus infection","volume":"26","author":"Bowman","year":"2017","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.antiviral.2018.09.012_bib3","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.09.012_bib4","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.00186-10","article-title":"Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance","volume":"54","author":"Chou","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.012_bib5","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.012_bib6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1208\/s12248-012-9337-6","article-title":"The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs","volume":"14","author":"Dahan","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.antiviral.2018.09.012_bib7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/clpt.2010.178","article-title":"Update on new antivirals under development for the treatment of double-stranded DNA virus infections","volume":"88","author":"Dropulic","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2018.09.012_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081583","article-title":"Interaction network of proteins associated with human cytomegalovirus IE2-p86 protein during infection: a proteomic analysis","volume":"8","author":"Du","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2018.09.012_bib9","doi-asserted-by":"crossref","first-page":"14223","DOI":"10.1073\/pnas.2334032100","article-title":"Functional profiling of a human cytomegalovirus genome","volume":"100","author":"Dunn","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.09.012_bib10","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1128\/AAC.48.10.3918-3927.2004","article-title":"Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms","volume":"48","author":"Evers","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.012_bib11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2018.09.012_bib12","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1128\/AAC.01794-13","article-title":"Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure","volume":"58","author":"Goldner","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.012_bib13","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.012_bib14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1071\/MA15057","article-title":"Therapeutics to prevent congenital cytomegalovirus during pregnancy: what is available now and in the future?","volume":"36","author":"Hamilton","year":"2015","journal-title":"Microbiol. Australia"},{"key":"10.1016\/j.antiviral.2018.09.012_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097231","article-title":"Human cytomegalovirus replication is strictly inhibited by siRNAs targeting UL54, UL97 or UL122\/123 gene transcripts","volume":"9","author":"Hamilton","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2018.09.012_bib16","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1128\/AAC.04534-14","article-title":"A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations","volume":"59","author":"Hutterer","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.012_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.antiviral.2013.04.017","article-title":"Profiling of the kinome of cytomegalovirus-infected cells reveals the functional importance of host kinases Aurora A, ABL and AMPK","volume":"99","author":"Hutterer","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.09.012_bib18","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1128\/AAC.43.8.1888","article-title":"Nonnucleoside pyrrolopyrimidines with a unique mechanism of action against human cytomegalovirus","volume":"43","author":"Jacobson","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.012_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/cpdd.388","article-title":"Pharmacokinetics and safety of letermovir coadministered with cyclosporine a or tacrolimus in healthy subjects","volume":"7","author":"Kropeit","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.antiviral.2018.09.012_bib20","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/nar\/gks1314","article-title":"Evidence that a consensus element found in naturally intronless mRNAs promotes mRNA export","volume":"41","author":"Lei","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2018.09.012_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiv352","article-title":"Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228)","volume":"213","author":"Lischka","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.012_bib22","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1128\/MCB.26.5.1631-1643.2006","article-title":"The UL69 transactivator protein of human cytomegalovirus interacts with DEXD\/H-Box RNA helicase UAP56 to promote cytoplasmic accumulation of unspliced RNA","volume":"26","author":"Lischka","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.antiviral.2018.09.012_bib23","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1128\/AAC.44.6.1588-1597.2000","article-title":"Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents","volume":"44","author":"Marschall","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.012_bib24","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1128\/AAC.05908-11","article-title":"In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses","volume":"56","author":"Marschall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.012_bib25","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1099\/0022-1317-82-6-1439","article-title":"Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97","volume":"82","author":"Marschall","year":"2001","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2018.09.012_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005825","article-title":"The prolyl isomerase Pin1 promotes the herpesvirus-induced phosphorylation-dependent disassembly of the nuclear lamina required for nucleocytoplasmic egress","volume":"12","author":"Milbradt","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.09.012_bib27","series-title":"Cytomegaloviruses. Fields Virology","first-page":"1960","author":"Mocarski","year":"2013"},{"key":"10.1016\/j.antiviral.2018.09.012_bib28","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1074\/mcp.M900485-MCP200","article-title":"A targeted spatial-temporal proteomics approach implicates multiple cellular trafficking pathways in human cytomegalovirus virion maturation","volume":"9","author":"Moorman","year":"2010","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.antiviral.2018.09.012_bib29","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S1473-3099(17)30143-3","article-title":"Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy","volume":"17","author":"Rawlinson","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.012_bib30","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1021\/jm950835y","article-title":"Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and thiosangivamycin: the effect of certain 4- and 4,6-substituents on the antiviral activity of pyrrolo[2,3-d]pyrimidines","volume":"39","author":"Renau","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.09.012_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0166-3542(92)90053-8","article-title":"Improved synthesis and biological evaluation of an acyclic thiosangivamycin active against human cytomegalovirus","volume":"19","author":"Renau","year":"1992","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.09.012_bib32","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1128\/AAC.31.4.544","article-title":"Pyrrolo[2,3-d]pyrimidine nucleosides as inhibitors of human cytomegalovirus","volume":"31","author":"Turk","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.012_bib33","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1128\/JVI.76.12.5893-5904.2002","article-title":"Association of herpes simplex virus type 1 ICP8 and ICP27 proteins with cellular RNA polymerase II holoenzyme","volume":"76","author":"Zhou","year":"2002","journal-title":"J. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218303905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218303905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T06:20:45Z","timestamp":1605075645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218303905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":33,"alternative-id":["S0166354218303905"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.09.012","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activity","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}